Preliminary studies with azapropazone in gout and hyperuricaemia

Eight patients with acute gouty arthritis were treated with high dose oral azapropazone 600 mg qds in an open study in order to evaluate its therapeutic potential in acute gout. The drug appeared to be as effective as previous agents used in the management of individual patient's acute gout wit...

Full description

Saved in:
Bibliographic Details
Published inEuropean journal of rheumatology and inflammation Vol. 6; no. 2; p. 149
Main Authors Thomas, A L, Majoos, F L, Nuki, G
Format Journal Article
LanguageEnglish
Published England 1983
Subjects
Adult
Aged
Apazone - adverse effects
Apazone - therapeutic use
Apazone - toxicity
Drug Evaluation
Female
Gout - drug therapy
Humans
Male
Middle Aged
Triazines - therapeutic use
Uric Acid - blood
Uric Acid - urine
Online AccessGet more information

Cover

More Information
Summary:Eight patients with acute gouty arthritis were treated with high dose oral azapropazone 600 mg qds in an open study in order to evaluate its therapeutic potential in acute gout. The drug appeared to be as effective as previous agents used in the management of individual patient's acute gout with resolution of pain in 2-21 days, and it had a potent hypouricaemic and uricosuric effect. The uricosuric effect of azapropazone 300 mg qds and phenylbutazone 100 mg tds was compared in a seven day cross-over study in seven asymptomatic patients with gout and hyperuricaemia. Azapropazone had a more rapid uricosuric effect than phenylbutazone. There was a statistically significant fall in serum uric acid and rise in uric acid clearance 24 hours after starting azapropazone and 72 hours following phenylbutazone.
ISSN:0140-1610